

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

15 Jun 2026

### Added value of multifidus dry needling in improving pain and function in females with patellofemoral pain: A randomized clinical trial study

#### Protocol summary

##### Study aim

Added value of multifidus dry needling in improving pain and function in females with patellofemoral pain

##### Design

A controlled, double group, single blinded (assessor), randomized (Randomizer site), phase 3 clinical trial on 60 patients.

##### Settings and conduct

The study at Shiraz's School of Rehabilitation Sciences will investigate on the added value of multifidus dry needling in improving pain and function in females with patellofemoral pain. The experimental group received dry needling (DN) of the lumbar multifidus and quadriceps, and the control group received DN of the quadriceps only, three days per week for one week. Blinding of evaluator is maintained by separating treatment and assessment roles.

##### Participants/Inclusion and exclusion criteria

Inclusion Criteria: Non-traumatic anterior knee pain ( $\geq 3$  months), age 18-40, pain intensity (NPRS) 3-6 in the past week, pain during  $\geq 2$  patellofemoral loading activities, positive Clarke's sign, and Kujala score  $< 80$ .  
Exclusion Criteria: Osteoarthritis; ligament/meniscus injury; patellar instability; plica syndrome; Osgood-Schlatter or Sinding-Larsen-Johansson syndrome; structural deformities or known pathology in the lower back, hip, or ankle; metabolic/neurological diseases (e.g., diabetes, radicular pain); contraindications to DN (cardiovascular disease, coagulopathy, anticoagulants, pregnancy, cancer, needle phobia); physiotherapy for knee pain in the past year; knee surgery history; acupuncture/injection/DN to knee or quadriceps in the past 6 months; bleeding disorders; or central/peripheral neurological pathology.

##### Intervention groups

Participants in the intervention group will receive DN targeting both the lumbar multifidus and quadriceps femoris muscles. The other group receive only quadriceps femoris DN.

#### Main outcome variables

Pain intensity, Physical function, Pressure Pain Threshold

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20250629066291N4**

Registration date: **2026-06-04, 1405/03/14**

Registration timing: **prospective**

Last update: **2026-06-04, 1405/03/14**

Update count: **0**

##### Registration date

2026-06-04, 1405/03/14

##### Registrant information

##### Name

Farzaneh Haghghat

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 71 3230 5410

##### Email address

haghghat\_fa@yahoo.com

##### Recruitment status

**Not yet recruiting**

##### Funding source

##### Expected recruitment start date

2026-06-20, 1405/03/30

##### Expected recruitment end date

2027-01-20, 1405/10/30

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

**Trial completion date**

empty

**Scientific title**

Added value of multifidus dry needling in improving pain and function in females with patellofemoral pain: A randomized clinical trial study

**Public title**

Added value of multifidus dry needling in improving pain and function in females with patellofemoral pain

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

Age range: 18 to 40 years Complaint of anterior knee pain (pain around or behind the patella) that was not related to trauma and had persisted for at least 3 months. The intensity of knee pain in the past week, according to the Numeric Pain Rating Scale (NPRS), reported by the patient: between 3 and 6 Report of pain during at least two load-bearing activities on the patellofemoral joint, including: ascending or descending stairs, squatting, prolonged sitting with the knee flexed, jumping activities, and running Positive Clarke's sign test Score on the Kujala Anterior Knee Pain Scale (AKPS): less than 80 Completion of the informed consent form

**Exclusion criteria:**

Osteoarthritis Ligament or meniscus injury Patellar instability, plica syndrome, Osgood-Schlatter disease, and Sinding-Larsen-Johansson syndrome Obvious structural deformities and known pathological conditions in the lower back, hip, and ankle Diagnosis of metabolic or neurological diseases such as diabetes or radicular pain Contraindications for dry needling, such as cardiovascular disease, coagulation disorders, use of anticoagulant medications, pregnancy, cancer, or needle phobia Receiving physiotherapy for knee pain within the past year History of knee surgery Receiving acupuncture, injection, or dry needling therapy for the knee or quadriceps muscles within the past 6 months Medical history of bleeding disorders Presence of central or peripheral neurological pathology

**Age**

From **18 years** old to **40 years** old

**Gender**

Female

**Phase**

3

**Groups that have been masked**

- Outcome assessor

**Sample size**

Target sample size: **60**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

The random assignment method in this study will be the blocked permutation method (number of blocks 8 and block size 4) which will be generated using randomizer site. The samples will be assigned in a 1:1 ratio. Opaque, sealed envelopes will be used to conceal the assignment.

**Blinding (investigator's opinion)**

Single blinded

**Blinding description**

The individual who performs the assessments is separate from the one who administers the treatments, and neither is aware of the other's work. The person responsible for randomization is also independent from both of the aforementioned individuals.

**Placebo**

Not used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics committee of Shiraz University of Medical Sciences

**Street address**

Ethics committee, Research and Technology Vice-Chancellor, 7th floor, Central building of Shiraz University of Medical Sciences, Zand Street

**City**

shiraz

**Province**

Fars

**Postal code**

7198754361

**Approval date**

2026-03-11, 1404/12/20

**Ethics committee reference number**

IR.SUMS.REC.1405.127

**Health conditions studied****1****Description of health condition studied**

Unilateral Patellofemoral pain

**ICD-10 code**

M22.2X9

**ICD-10 code description**

Patellofemoral disorders, unspecified knee

**Primary outcomes****1****Description**

pain intensity

**Timepoint**

Before intervention; One day after intervention period

**Method of measurement**

Numeric Pain Rating Scale (NPRS)

## 2

### **Description**

Physical Function

### **Timepoint**

Before intervention; One day after intervention period

### **Method of measurement**

Kujala Questionnaire (Anterior Knee Pain Scale, AKPS)-step down - mSEBT

## 3

### **Description**

Pressure Pain Threshold

### **Timepoint**

Before intervention; One day after intervention period

### **Method of measurement**

Algometer

## **Secondary outcomes**

empty

## **Intervention groups**

### 1

#### **Description**

Intervention group: In the intervention group, dry needling of the lumbar multifidus and quadriceps femoris muscles will be performed three days per week (on alternate days) for one week. Dry needling will be administered by an experienced and trained physiotherapist. Throughout the treatment, a “clean technique” will be employed, which includes handwashing, the use of non-latex examination gloves, and skin preparation with an alcohol swab prior to needle insertion. With the participant lying in a relaxed prone position, the multifidus muscle will be palpated in the region immediately lateral and adjacent to the interspinous spaces of the L4/L5 and L5/S1 vertebral levels, as determined by the examiner. To locate the L4/L5 and L5/S1 levels, the L4 vertebral level will first be identified by palpating the bilateral iliac crests, then tracing the intercrystal line posterior-medially to its intersection with the lumbar spine. This intersection point is considered the L3/L4 interspinous space. The examiner will then palpate caudally to identify the L4/L5 and L5/S1 interspinous spaces, thereby determining the L4/L5 and L5/S1 vertebral levels. (It should be noted that these anatomical landmarks can vary between individuals, which may present a significant challenge for precise vertebral level identification via palpation.) To detect the presence of myofascial trigger points—defined as palpable, painful nodules within muscle tissue (whether active or latent)—the identified sites will be treated with dry needling. While each participant remains in the prone position, a solid, sterile, single-use needle will be inserted bilaterally into the lumbar multifidus muscles at the L3, L4, and L5 vertebral levels. Needle size (either 0.25 × 50 mm or 0.25 × 40 mm; Dongbang Medical, Korea) will be selected based on the participant’s body habitus.

### **Category**

Treatment - Other

## 2

### **Description**

Control group: In the control group, dry needling of the quadriceps femoris muscle alone will be administered as same as intervention group three days per week (on alternate days) for a total of one week.

### **Category**

Treatment - Other

## **Recruitment centers**

### 1

#### **Recruitment center**

##### **Name of recruitment center**

Clinic of Rehabilitation School, Shiraz University of Medical Sciences

##### **Full name of responsible person**

Farzaneh Haghghat

##### **Street address**

Mehr Building, Shahid Chamran Hospital, Shahid Chamran Boulevard

##### **City**

shiraz

##### **Province**

Fars

##### **Postal code**

7194815644

##### **Phone**

+98 71 3624 0101

##### **Email**

rehabdep@sums.ac.ir

## **Sponsors / Funding sources**

### 1

#### **Sponsor**

##### **Name of organization / entity**

Shiraz University of Medical Sciences

##### **Full name of responsible person**

Hamid Mohammadi

##### **Street address**

Research and Technology Vice-Chancellor, 7th floor, Central building of Shiraz University of Medical Sciences, Zand Street

##### **City**

shiraz

##### **Province**

Fars

##### **Postal code**

7134814336

##### **Phone**

+98 71 3212 2430

##### **Email**

vcrdep@sums.ac.ir

#### **Grant name**

#### **Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Shiraz University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Academic

**Person responsible for general inquiries****Contact****Name of organization / entity**

Shiraz University of Medical Sciences

**Full name of responsible person**

Farzaneh Haghighat

**Position**

Assistant Professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Physiotherapy

**Street address**

Mehr Building, Shahid Chamran Hospital, Shahid Chamran Boulevard

**City**

shiraz

**Province**

Fars

**Postal code**

7194815644

**Phone**

+98 71 3624 0101

**Email**

haghighat\_fa@yahoo.com

**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Shiraz University of Medical Sciences

**Full name of responsible person**

Farzaneh Haghighat

**Position**

Assistant Professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Physiotherapy

**Street address**

Mehr Building, Shahid Chamran Hospital, Shahid Chamran Boulevard

**City**

shiraz

**Province**

Fars

**Postal code**

7194815644

**Phone**

+98 71 3624 0101

**Email**

haghighat\_fa@yahoo.com

**Person responsible for updating data****Contact****Name of organization / entity**

Shiraz University of Medical Sciences

**Full name of responsible person**

Farzaneh Haghighat

**Position**

Assistant Professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Physiotherapy

**Street address**

Mehr Building, Shahid Chamran Hospital, Shahid Chamran Boulevard

**City**

shiraz

**Province**

Fars

**Postal code**

7194815644

**Phone**

+98 71 3624 0101

**Email**

haghighat\_fa@yahoo.com

**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Yes - There is a plan to make this available

**Informed Consent Form**

Yes - There is a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

Not applicable

**Data Dictionary**

Not applicable

**Title and more details about the data/document**

Information collection form including primary outcomes, informed consent form and SPSS file

**When the data will become available and for how long**

After publication the results of the study

**To whom data/document is available**

Researchers working in academic and scientific

institutions

**Under which criteria data/document could be used**

Only for recording information in scientific databases

**From where data/document is obtainable**

Correspondence with the project manager by email.

Haghighat\_fa@yahoo.com

**What processes are involved for a request to access data/document**

Maximum one month after sending the request by email

**Comments**